Central Nervous System Biomarkers Market Size, Trends [2031]
Central Nervous System Biomarkers Market Size, Trends [2031]
Segments - Central Nervous System Biomarkers Market by Applications (Drug Discovery and Development, Personalized Medicine, and Other Applications) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028
Upcoming
| Report ID :HC-1126
| 4.8 Rating
| 69 Reviews
| 185 Pages
| Format :
Report Description
The global central nervous system biomarkers market size was valued at USD 4,652 million in 2020 and is expanding at considerable a CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the biomarkers for the central nervous system that have progressed in terms of technology.
A biomarker is a molecule that is used to assess the biological condition, the existence of illnesses, and the treatment effects. Over the last decade, advances in genomics and proteomics have increased understanding of genetic regulatory mechanisms associated with (central nervous system) CNS biomarkers. Through a comparison of normal and sick tissues, proteomics technologies have improved in numerous fields of drug discovery and development. The identification of useful protein biomarkers in both diagnostics and treatments for the central nervous system is a major goal of proteomics research. It is critical in the early diagnosis, prognosis, and monitoring of illness.
According to our database, global GDP fell by 4.5 per cent in May 2021, resulting in a loss of USD 3.94 trillion in economic activity. The consequences were also seen in the worldwide market for CNS biomarkers. In the early stages of the pandemic, the rate of patient screening and diagnosis was significantly hampered because governments throughout the world-imposed restrictions such as lockdowns to prevent the illness from spreading. According to a report released by the American Cancer Society in 2021, delays in cancer screening, diagnosis, and treatment would almost certainly result in a short-term decrease in cancer diagnoses, followed by an increase in late-stage diagnoses and unnecessary cancer deaths due to limited healthcare coverage.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing use of CNS biomarkers in neurodegenerative disease diagnosis is projected to spur market expansion in the coming years.
- Expensive biomarker testing and diagnostics for the central nervous system is estimated to hinder the market growth.
- Biomarkers of the central nervous system and their regulatory implications is expected to impede market growth.
- Growing number of diseases and improvement in the healthcare infrastructure is anticipated to create immense opportunities for the market players.
Scope of the Report
The report on the global central nervous system biomarkers market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Central Nervous System Biomarkers Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2020 |
|
Historic Data |
2018–2019 |
|
Forecast Period |
2021–2028 |
|
Segmentation |
Applications (Drug Discovery and Development, Personalized Medicine, and Other Applications) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
Thermo fisher scientific, Enzo biochem inc, Abiant Inc, EKF diagnostics holdings Inc, Abastar MDX Inc, Acumen pharmaceuticals Inc, Adlyfe Inc, Apitope international, Alseres pharmaceuticals Inc, Aposense, Banyan biomarkers, Avid radiopharmaceuticals Inc, Diagenic ASA, Avacta Group plc, Applied neurosolutions Inc, Merc & co. Inc, and Exonhit therapeutics |
Market Segment Insights
Personalized medicine segment is projected to account for a key market share
In terms of applications, the central nervous system biomarkers market is segregated into drug discovery and development, personalized medicine, and other applications. The personalized medicine segment is expected to account for a key share of the market during the forecast period owing to the growing frequency of the brain and other nervous system tumors. It is finding increasing use as a diagnostic tool, assisting in the identification of precise biological markers. A growing number of firms are focusing their efforts on creating breakthrough solutions for the treatment of neurological disorders.
Biomarker research in neurodegenerative illness is a field of personalized medicine that is fast progressing. These indicators can be used for more than just diagnosis; they can also be used to predict prognosis or aid in the development of novel treatments. As a result, a significant number of compounds have been studied and linked to various neurodegenerative diseases. The two most prevalent neurodegenerative illnesses are Alzheimer's disease and Parkinson's disease.
North America is expected to dominate the market
On the basis of regions, the central nervous system biomarkers market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to expand at an impressive CAGR during the forecast period. The regional market growth can be attributed to the rising burden of chronic illnesses, advances in proteomics, genomics, and imaging technologies.
According to GLOBOCAN projections, in 2020, there will be 2,281,658 new cancer cases diagnosed and 612,390 cancer-related deaths in the United States. The National Institute of Neurological Disorders and Stroke is largely focused on methods that might speed up the development and validation of reliable biomarkers, particularly for improved diagnosis and treatment of specific diseases.
Segments
Segments Covered in the Report
The global central nervous system biomarkers market has been segmented on the basis of
Applications
- Drug Discovery and Development
- Personalized Medicine
- Other Applications
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Thermo fisher scientific
- Enzo biochem inc
- Abiant Inc
- EKF diagnostics holdings Inc
- Abastar MDX Inc
- Acumen Pharmaceuticals Inc
- Adlyfe Inc
- Apitope international
- Alseres pharmaceuticals Inc
- Aposense
- Banyan biomarkers
- Avid radiopharmaceuticals Inc
- Diagenic ASA
- Avacta Group plc
- Applied neurosolutions Inc
- Merc & co. Inc
- Exonhit therapeutics
Competitive Landscape
Key players competing in the central nervous system biomarkers market include Thermo fisher scientific, Enzo biochem inc, Abiant Inc, EKF diagnostics holdings Inc, Abastar MDX Inc, Acumen pharmaceuticals Inc, Adlyfe Inc, Apitope international, Alseres pharmaceuticals Inc, Aposense, Banyan biomarkers, Avid radiopharmaceuticals Inc, Diagenic ASA, Avacta Group plc, Applied neurosolutions Inc, Merc & co. Inc, and Exonhit therapeutics.
Table Of Content
1. Executive Summary2. Assumptions and Acronyms Used
3. Research Methodology
4. Central Nervous System Biomarkers Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Central Nervous System Biomarkers Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Central Nervous System Biomarkers Market - Supply Chain
4.5. Global Central Nervous System Biomarkers Market Forecast
4.5.1. Central Nervous System Biomarkers Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Central Nervous System Biomarkers Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Central Nervous System Biomarkers Market Absolute $ Opportunity
5. Global Central Nervous System Biomarkers Market Analysis and Forecast by Region
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Region
5.2.2. Y-o-Y Growth Projections by Region
5.3. Central Nervous System Biomarkers Market Size and Volume Forecast by Region
5.3.1. North America
5.3.2. Latin America
5.3.3. Europe
5.3.4. Asia Pacific
5.3.5. Middle East and Africa (MEA)
5.4. Absolute $ Opportunity Assessment by Region
5.5. Market Attractiveness/Growth Potential Analysis by Region
5.6. Global Central Nervous System Biomarkers Demand Share Forecast, 2019-2026
6. North America Central Nervous System Biomarkers Market Analysis and Forecast
6.1. Introduction
6.1.1. Basis Point Share (BPS) Analysis by Country
6.1.2. Y-o-Y Growth Projections by Country
6.2. North America Central Nervous System Biomarkers Market Size and Volume Forecast by Country
6.2.1. U.S.
6.2.2. Canada
6.3. Absolute $ Opportunity Assessment by Country
6.4. Market Attractiveness/Growth Potential Analysis
6.4.1. By Country
6.4.2. By Product Type
6.4.3. By Application
6.5. North America Central Nervous System Biomarkers Demand Share Forecast, 2019-2026
7. Latin America Central Nervous System Biomarkers Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.1.3. Latin America Average Pricing Analysis
7.2. Latin America Central Nervous System Biomarkers Market Size and Volume Forecast by Country
7.2.1. Brazil
7.2.2. Mexico
7.2.3. Rest of Latin America
7.3. Absolute $ Opportunity Assessment by Country
7.4. Market Attractiveness/Growth Potential Analysis
7.4.1. By Country
7.4.2. By Product Type
7.4.3. By Application
7.5. Latin America Central Nervous System Biomarkers Demand Share Forecast, 2019-2026
8. Europe Central Nervous System Biomarkers Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Europe Average Pricing Analysis
8.2. Europe Central Nervous System Biomarkers Market Size and Volume Forecast by Country
8.2.1. Germany
8.2.2. France
8.2.3. Italy
8.2.4. U.K.
8.2.5. Spain
8.2.6. Russia
8.2.7. Rest of Europe
8.3. Absolute $ Opportunity Assessment by Country
8.4. Market Attractiveness/Growth Potential Analysis
8.4.1. By Country
8.4.2. By Product Type
8.4.3. By Application
8.5. Europe Central Nervous System Biomarkers Demand Share Forecast, 2019-2026
9. Asia Pacific Central Nervous System Biomarkers Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Asia Pacific Average Pricing Analysis
9.2. Asia Pacific Central Nervous System Biomarkers Market Size and Volume Forecast by Country
9.2.1. China
9.2.2. Japan
9.2.3. South Korea
9.2.4. India
9.2.5. Australia
9.2.6. Rest of Asia Pacific (APAC)
9.3. Absolute $ Opportunity Assessment by Country
9.4. Market Attractiveness/Growth Potential Analysis
9.4.1. By Country
9.4.2. By Product Type
9.4.3. By Application
9.5. Asia Pacific Central Nervous System Biomarkers Demand Share Forecast, 2019-2026
10. Middle East & Africa Central Nervous System Biomarkers Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Middle East & Africa Average Pricing Analysis
10.2. Middle East & Africa Central Nervous System Biomarkers Market Size and Volume Forecast by Country
10.2.1. Saudi Arabia
10.2.2. South Africa
10.2.3. UAE
10.2.4. Rest of Middle East & Africa (MEA)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Market Attractiveness/Growth Potential Analysis
10.4.1. By Country
10.4.2. By Product Type
10.4.3. By Application
10.5. Middle East & Africa Central Nervous System Biomarkers Demand Share Forecast, 2019-2026
11. Competition Landscape
11.1. Global Central Nervous System Biomarkers Market: Market Share Analysis
11.2. Central Nervous System Biomarkers Distributors and Customers
11.3. Central Nervous System Biomarkers Market: Competitive Dashboard
11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
11.4.1. Thermo fisher scientific
11.4.2. Enzo biochem inc
11.4.3. Abiant Inc
11.4.4. EKF diagnostics holdings Inc
11.4.5. Abastar MDX Inc
11.4.6. Acumen Pharmaceuticals Inc
Methodology
Related Reports
Some other reports from this category!
Our Clients
